These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15173064)

  • 1. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases.
    Miyakoshi S; Yuji K; Kami M; Kusumi E; Kishi Y; Kobayashi K; Murashige N; Hamaki T; Kim SW; Ueyama J; Mori S; Morinaga S; Muto Y; Masuo S; Kanemaru M; Hayashi T; Takaue Y; Taniguchi S
    Clin Cancer Res; 2004 Jun; 10(11):3586-92. PubMed ID: 15173064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases.
    Miyakoshi S; Kami M; Tanimoto T; Yamaguchi T; Narimatsu H; Kusumi E; Matsumura T; Takagi S; Kato D; Kishi Y; Murashige N; Yuji K; Uchida N; Masuoka K; Wake A; Taniguchi S
    Transplantation; 2007 Aug; 84(3):316-22. PubMed ID: 17700155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma.
    Yuji K; Miyakoshi S; Kato D; Miura Y; Myojo T; Murashige N; Kishi Y; Kobayashi K; Kusumi E; Narimatsu H; Hamaki T; Matsumura T; Kami M; Fukuda T; Masuo S; Masuoka K; Wake A; Ueyama J; Yoneyama A; Miyamoto K; Nagoshi H; Matsuzaki M; Morinaga S; Muto Y; Takeue Y; Taniguchi S;
    Biol Blood Marrow Transplant; 2005 Apr; 11(4):314-8. PubMed ID: 15812397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
    Kusumi E; Kami M; Yuji K; Hamaki T; Murashige N; Hori A; Kojima R; Kishi Y; Kim SW; Ueyama J; Miyakoshi S; Tanosaki R; Morinaga S; Mori S; Heike Y; Muto Y; Masuo S; Taniguchi S; Takaue Y
    Bone Marrow Transplant; 2004 Apr; 33(7):697-702. PubMed ID: 14755317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.
    Komatsu T; Narimatsu H; Yoshimi A; Kurita N; Kusakabe M; Hori A; Murashige N; Matsumura T; Kobayashi K; Yuji K; Tanaka Y; Kami M
    Ann Hematol; 2007 Jan; 86(1):49-54. PubMed ID: 17036221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation.
    Abu-Ghosh A; Goldman S; Slone V; van de Ven C; Suen Y; Murphy L; Sender L; Cairo M
    Bone Marrow Transplant; 1999 Sep; 24(5):535-44. PubMed ID: 10482939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
    Falda M; Busca A; Baldi I; Mordini N; Bruno B; Allione B; Rambaldi A; Morello E; Narni F; Santarone S; Locatelli F; Bacigalupo A;
    Am J Hematol; 2007 Oct; 82(10):863-6. PubMed ID: 17616972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Okada M; Fujimori Y; Misawa M; Kai S; Nakajima T; Okikawa Y; Satake A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Tamaki H; Ikegame K; Hara H; Ogawa H
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of unrelated donor umbilical cord blood transplantation for 30 adults with hematological malignancies.
    Kobayashi K; Maeda Y; Hara Y; Nishie-Kataoka M; Nishimori H; Sugiyama H; Namba N; Kubonishi S; Niiya M; Shinagawa K; Ikeda K; Tanimoto M
    Anticancer Res; 2009 May; 29(5):1763-70. PubMed ID: 19443401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
    Tan PL; Wagner JE; Auerbach AD; Defor TE; Slungaard A; Macmillan ML
    Pediatr Blood Cancer; 2006 May; 46(5):630-6. PubMed ID: 16078221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
    Rodrigues CA; Sanz G; Brunstein CG; Sanz J; Wagner JE; Renaud M; de Lima M; Cairo MS; Fürst S; Rio B; Dalley C; Carreras E; Harousseau JL; Mohty M; Taveira D; Dreger P; Sureda A; Gluckman E; Rocha V
    J Clin Oncol; 2009 Jan; 27(2):256-63. PubMed ID: 19064984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.